SCHEMBL10560587

SCHEMBL10560587

COc1cc2ccccc2c(OC)c1C(=O)Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.47
HPGD P15428 5/20 0.47
KDM4E B2RXH2 5/20 0.47
NPSR1 Q6W5P4 3/20 0.47
ERN1 O75460 1/20 0.47
NQO1 P15559 1/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPT P10636 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
PKM P14618 1/20 0.43
PTGES O14684 1/20 0.43
ALOX5 P09917 1/20 0.43
CTSD P07339 1/20 0.42
ALOX15 P16050 1/20 0.41
POLB P06746 1/20 0.40
HTT P42858 1/20 0.40
TUBB4A P04350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6604677 0.88 CTSD (0.48) ALDH1A1HPGDKDM4ENPSR1ERN1
SCHEMBL27626385 0.86 CA12 (0.50) ALDH1A1HPGDKDM4ENPSR1ERN1
SCHEMBL7616763 0.86 KDM4E (0.54) ALDH1A1HPGDKDM4ENPSR1ERN1
SCHEMBL27697072 0.83 CTSD (0.50) ALDH1A1HPGDKDM4ENPSR1ERN1
SCHEMBL7471611 0.82 ALDH1A1 (0.44) ALDH1A1HPGDKDM4ENPSR1ERN1
SCHEMBL8967497 0.81 KDM4E (0.51) ALDH1A1HPGDKDM4ENPSR1MAPT
SCHEMBL14134452 0.79 CYP1A2 (0.45) ALDH1A1HPGDKDM4ENPSR1ERN1
SCHEMBL21525442 0.79 ALDH1A1 (0.43) ALDH1A1HPGDKDM4ENPSR1ERN1
SCHEMBL3622482 0.79 KMT2A (0.53) ALDH1A1HPGDKDM4EHSD17B10MAPT
SCHEMBL2770226 0.77 KDM4E (0.42) ALDH1A1HPGDKDM4ENPSR1ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-4804679-A INHIBIT CHOLESTEROL BIOSYNTHESIS SANDOZ PHARM. CORP. (US) 1989-02-14 US disclosed
US-4686237-A LOWERING BLOOD CHOLESTEROL LEVEL SANDOZ PHARMACEUTICALS CORP. (US) 1987-08-11 US disclosed
EP-0117228-A1 Analogs of mevalonolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals SANDOZ AG (CH) 1984-08-29 EP disclosed
WO-1984002903-A1 MEVALONOLACTONE ANALOGS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS SANDOZ AG (CH) 1984-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF ALDH1A1 1614/4885HPGD 2930/4885KDM4E 1012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.